Taeyoung Yun

Taeyoung Yun

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2022 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
TYTaeyoung Yun
Taeyoung Yun
HKHakju Kim
Hakju Kim
BSBongyeon Sohn
Bongyeon Sohn
HCHyoung Woo Chang
Hyoung Woo Chang
CLCheong Lim
Cheong Lim
PHPh.D.
Ph.D.
Taeyoung Yun, M.D., Hakju Kim, M.D., Bongyeon Sohn, M.D., Hyoung Woo Chang, M.D., Ph.D., Cheong Lim, M.D., Ph.D., Kay-Hyun Park, M.D., Ph.D.. J Chest Surg 2022;55:55-60. https://doi.org/10.5090/jcs.21.111

23 April 2024 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
SBSeon Yong Bae
Seon Yong Bae
TYTaeyoung Yun
Taeyoung Yun
JPJi Hyeon Park
Ji Hyeon Park
BNBubse Na
Bubse Na
KNKwon Joong Na
Kwon Joong Na
YKYoung Tae Kim
Young Tae Kim
Seon Yong Bae, M.D., Taeyoung Yun, M.D., Ji Hyeon Park, M.D., Bubse Na, M.D., Kwon Joong Na, M.D., Samina Park, M.D., Hyun Joo Lee, M.D., Ph.D., In Kyu Park, M.D., Ph.D., Chang Hyun Kang, M.D., Ph.D., Young Tae Kim, M.D., Ph.D.. J Chest Surg 2024;57:450-7. https://doi.org/10.5090/jcs.24.008

1 December 2025 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
TYTaeyoung Yun
Taeyoung Yun
BKByeong Ju Koo
Byeong Ju Koo
KNKwon Joong Na
Kwon Joong Na
SLSangjun Lee
Sangjun Lee
JPJi Hyeon Park
Ji Hyeon Park
YKYoung Tae Kim
Young Tae Kim
Objectives: To compare postoperative lung function and volume compensation in lung cancer patients after lobectomy or segmentectomy. Methods: We retrospectively reviewed patients who underwent initial lung cancer surgery between 2019 and 2021. Of 1076 patients, 870 underwent lobectomy and 206 segmentectomy. Propensity score matching (PSM) of 1:2 was performed using age, sex, smoking status, and preoperative pulmonary function tests (PFTs). Total lung volume (TLV) was calculated using deep learning-assisted 3D lung segmentation on thin-section computed tomography images. Postoperative lung volumes were compared with predicted postoperative (PPO) volumes and correlated with PFT results. Results: After matching, 378 lobectomy and 189 segmentectomy patients were included. TLV reduction was similar between groups, but contralateral lung volume (CLV) increased more after lobectomy (P = .010). Diffusing capacity of the lung for carbon monoxide was better preserved after segmentectomy (P = .029), whereas force vital capacity and forced expiratory volume in 1 second (FEV1) were similar. Actual postoperative PFT values exceeded predicted values in both groups, but the discrepancy was larger after lobectomy (P < .001). In segmentectomy, single-segment resection showed no compensation, while multiple-segment resections had variable compensation patterns. Ipsilateral lung volume changes contributed more than CLV changes, and compensation patterns varied by lobe. The TLV change correlated with forced vital capacity and FEV1 but not diffusing capacity of the lung for carbon monoxide. Conclusions: Lobectomy induced greater CLV compensation than segmentectomy. Although overall lung function preservation was similar, lobectomy resulted in a greater difference between actual and PPO pulmonary function.

1 October 2025 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
TYTaeyoung Yun
Taeyoung Yun
SLSangjun Lee
Sangjun Lee
JPJi Hyeon Park
Ji Hyeon Park
BNBubse Na
Bubse Na
KNKwon Joong Na
Kwon Joong Na
SPSamina Park
Samina Park
Background: The potential association between preoperative percutaneous transthoracic needle biopsy (PTNB) and pleural recurrence in lung cancer remains controversial. This study aimed to determine whether PTNB increases the risk of pleural recurrence in patients with clinically diagnosed stage I non-small cell lung cancer (NSCLC). Methods: We retrospectively analyzed 1,733 patients with clinical stage I NSCLC who underwent surgical resection between January 2018 and December 2020. Patients were divided into the PTNB group (n=699) and the non-PTNB group (n=1,034). After 1:1 propensity score matching (PSM), risk factors for pleural recurrence were assessed using Fine-Gray subdistribution hazard models. Cumulative incidence rate and overall survival (OS) were also analyzed. Results: After matching, 530 patients were included in each group. Multivariate Fine-Gray analysis revealed that PTNB [subdistribution hazard ratio (sHR) =3.74; 95% confidence interval (CI): 1.06–13.20; P=0.040] and visceral pleural invasion (VPI) (sHR =3.12; 95% CI: 1.10–8.90; P=0.03) were independent risk factors for isolated pleural recurrence, whereas lymphatic invasion was not (sHR =2.32; 95% CI: 0.82–6.56; P=0.11). For all types of recurrence, PTNB, VPI, and lymphatic invasion were significant predictors (all P<0.05). A subgroup analysis was conducted in patients without VPI or lymphatic invasion (n=1,142; PTNB group =332, non-PTNB group =810), representing a low-risk cohort for pleural recurrence. After PSM, 320 patients were included in each group with well-balanced baseline characteristics. In this subgroup, PTNB remained a significant risk factor for isolated pleural recurrence in the univariate Fine-Gray analysis (sHR =2.29; 95% CI: 1.19–4.38; P=0.01) and for all recurrence types (sHR =2.13; 95% CI: 1.13–4.01; P=0.01). Pathologic tumor size was also consistently associated with increased recurrence risk. In multivariate models PTNB, non-adenocarcinoma histology, and larger pathological tumor size were associated with both isolated pleural and overall recurrence (all P<0.001). Conclusions: Preoperative PTNB was statistically correlated with an increased pleural recurrence in clinical stage I NSCLC, even among patients without conventional high-risk pathological features. Careful consideration is warranted when deciding on PTNB for early-stage disease.

27 December 2025 in Cancers
Verified
Journal Article
Open access
PDF file
BNBubse Na
Bubse Na
CKChang Hyun Kang
Chang Hyun Kang
TYTaeyoung Yun
Taeyoung Yun
JPJi Hyeon Park
Ji Hyeon Park
KNKwon Joong Na
Kwon Joong Na
HKHak Jae Kim
Hak Jae Kim
Background: Neoadjuvant chemotherapy is generally recommended for locally advanced, potentially resectable thymic epithelial tumors. However, neoadjuvant chemoradiotherapy has been proposed as an alternative approach, potentially achieving higher complete resection rates. In this study, a retrospective analysis was conducted to compare the outcomes of neoadjuvant chemoradiotherapy (NCRT) and neoadjuvant chemotherapy (NCT). Methods: From 2009 to 2022, a total of 98 patients who underwent surgery following either NCRT (n = 30) or NCT (n = 68) for thymic epithelial tumors were included in this study. Propensity score matching was applied, resulting in two matched groups of 30 patients each. The primary endpoint was the comparison of complete (R0) resection rates between the groups. Results: In the matched cohort, the R0 resection rate was significantly higher in the NCRT group (93.3%) compared to the NCT group (73.3%; p = 0.038). The tumor regression grade was also significantly lower in the NCRT group (p = 0.002). However, no significant difference was observed in 5-year overall survival between the groups, either in patients with thymoma (100% for NCRT vs. 90.9% for NCT; p = 0.34) or thymic carcinoma (74.3% for NCRT vs. 63.2% for NCT; p = 0.82). For patients with initial local recurrence, both the 5-year overall survival and post-recurrence survival rates were 100%. Conclusions: The neoadjuvant chemoradiotherapy group demonstrated superior local control, as evidenced by improved tumor regression grades and complete resection rates. However, the absence of corresponding improvement in overall survival warrants further investigation with a larger patient cohort and a longer follow-up period.

5 February 2022 in Journal of Chest Surgery
Verified
Journal Article
Open access
PDF file
TYTaeyoung Yun
Taeyoung Yun
HKHye Won Kwon
Hye Won Kwon
SPSamina Park
Samina Park
WKWoong-Han Kim
Woong-Han Kim
M.M.D.
M.D.
PHPh.D.
Ph.D.
Taeyoung Yun, M.D., Hye Won Kwon, M.D., Samina Park, M.D., Woong-Han Kim, M.D., Ph.D.. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.21.091